[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346667-105":59,"doc-detail-346667-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prevalence-of-brca1-promoter-methylation-in-cohorts-of-individuals-with-and-without-cancer-assessed-by-circulating-cell-free-dna","Prevalence of BRCA1 Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA","","BRCA1 promoter methylation (BRCA1meth) influences 20%–27% of triple-negative breast cancer and ovarian cancer and may help predict therapy response. Because constitutional BRCA1meth can also appear in peripheral blood without DNA mutation, a sensitive, tissue-free assay is important for cancer risk assessment and management. Using a GRAIL cfDNA-based targeted methylation platform, the study quantifies cfBRCA1meth in plasma from individuals with and without cancer to evaluate accuracy, prevalence patterns, and tumor-burden relevance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-of-brca1-promoter-methylation-in-cohorts-of-individuals-with-and-without-cancer-assessed-by-circulating-cell-free-dna/346667/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-of-brca1-promoter-methylation-in-cohorts-of-individuals-with-and-without-cancer-assessed-by-circulating-cell-free-dna/346667.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study's key objective regarding BRCA1 promoter methylation?","Question",{"text":112,"@type":113},"To determine whether BRCA1 promoter methylation can be detected in circulating cell-free DNA as a molecular biomarker in cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was BRCA1meth measured in the study?",{"text":117,"@type":113},"The study used the GRAIL circulating cell-free DNA targeted methylation platform to quantify cfBRCA1meth in plasma samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about cfBRCA1meth prevalence across different cohorts?",{"text":121,"@type":113},"cfBRCA1meth detection was sensitive and accurate, occurring in individuals without cancer and being enriched specifically in triple-negative breast cancer and ovarian cancer among a pan-cancer cohort.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346667,1790156654,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Original Reports | Precision Medicine  \nPrevalence of BRCA1 Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA  \nEdison T. Liu, MD, PhD1  ; Margaret Antonio, PhD2  ; Tracy Nance, PhD2  ; and Francesca Menghi, PhD1  DOI [https://doi.org/10.1200/PO-25-00854](https://doi.org/10.1200/PO-25-00854)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | BRCA1 promoter methylation (BRCA1meth) affects 20%-27% of triple-negative |\n| METHODS | breast cancer (TNBC) and ovarian cancer (OvCa) and has therapeutic predictive value in both cancer types. BRCA1meth is established during early embryonic development as a constitutional event, and its detection in the peripheral blood cells of unaffected women associateswith increased riskfor breast cancer and OvCa. Thus, facile and sensitive assessment ofBRCA1methis an important component for both risk assessment and the therapeutic management of these cancer types. We used the GRAIL circulating cell-free DNA (cfDNA)–based targeted methylation platform to quantify BRCA1meth in cfDNA (cfBRCA1meth) from plasma samples of individuals with and without cancer. |\n| RESULTS | Detection of cfBRCA1meth was accurate and sensitive, with an empirical LoD95 of [0.0081. cf](0.0081. cf)BRCA1meth was found in 4 .1%(113/2,790) of individuals without cancer, and it was signiﬁcantly more prevalent in females compared with males (4.8% v 2.9%, P 5 .016), suggesting that the dynamics of BRCA1 promoter methylation and its consequences for cancer development may differ by sex. In a pan-cancer cohort comprising 2,849 patients and representing 15 tissue types, cfBRCA1meth was enriched only in TNBC (15.2%, P 5 .001) and OvCa (13.9%, P 5 .014). Importantly, in these cfBRCA1meth-positive cases, the fraction of cfBRCA1meth was correlated with a methylation-based estimate of tumor burden. |\n| CONCLUSION | Our ﬁndings demonstrate that BRCA1meth can be robustly detected using cfDNA assessment both as a constitutional event in noncancer samples and as a metric of BRCA1meth tumor burden in individuals with BRCA1meth cancers. Therefore, the GRAIL assay provides a single quantitative platform that can be used to explore the role of BRCA1meth in cancer risk and therapeutic response. |\n\nACCOMPANYING CONTENT  \n Data Sharing Statement  \n Data Supplement  \nAccepted January 27, 2026 Published March 9, 2026  \nJCO Precis Oncol 10:e2500854 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nBACKGROUND  \nBRCA1 deﬁciency induced by BRCA1 promoter methylation (BRCA1meth) is found in the tumor tissue of 20%-27% of patients with ovarian cancer (OvCa) and triple-negative breast cancer (TNBC)1-4 and is considered causative in the development of these cancer types.5 Although BRCA1meth tumors share similar genomic signatures with BRCA1-mutant tumors,2 ,6 our previous work demonstrated that BRCA1meth associates with worse treatment response. This reduced sensitivity arises because BRCA1meth is frequently lost after chemotherapy exposure, leading to BRCA1 reexpression, restoration of homologous recombination proﬁciency, and acquired treatment resistance.2  \nRecently, BRCA1meth was observed constitutionally in the peripheral blood cells (PBCs) of 5%-9% of women  \nwithout cancer.5,7 This is generally recognized as a primary epimutation event, where an epigenetic change occurs in the absence of a DNA mutation, as opposed to a secondary epimutation, where an epigenetic change is triggered by acis- or trans-acting genetic mutation.8 Constitutional BRCA1meth typically affects a single allele and has a mosaic presentation, affecting a small fraction of somatic cells: the median BRCA1meth allelic fraction ranges between 0.01 and 0.05 (on a 0-1 scale), rarely reaching up to 0.3.5,7,9-12 Since BRCA1meth is detected in cord blood samples and in adult tissues from all germinal layers, and because of the intraindividual consistency of the affected a","cbCaiqpSiFUhJxtW","https://ap.wps.com/l/cbCaiqpSiFUhJxtW","pdf",1583161,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Background\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What is the study's key objective regarding BRCA1 promoter methylation?\",\"answer\":\"To determine whether BRCA1 promoter methylation can be detected in circulating cell-free DNA as a molecular biomarker in cancer.\"},{\"question\":\"How was BRCA1meth measured in the study?\",\"answer\":\"The study used the GRAIL circulating cell-free DNA targeted methylation platform to quantify cfBRCA1meth in plasma samples.\"},{\"question\":\"What did the study find about cfBRCA1meth prevalence across different cohorts?\",\"answer\":\"cfBRCA1meth detection was sensitive and accurate, occurring in individuals without cancer and being enriched specifically in triple-negative breast cancer and ovarian cancer among a pan-cancer cohort.\"}]","Prevalence of BRCA1 Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA | PDF",1790062342,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64f3a8b952fae05017db9f4952728b3a.webp",983,1315,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1831fb3308e61e06762877d43fca56d5.webp",982,1314,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/923179c9b4571eae77d2194b5378692a.webp",981,1312,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ce1d6b5607476dfd86e63fd215a19ef.webp",980,1311]